US › Healthcare

Inventiva Sa (IVA)

US · Healthcare · Biotechnology

$3.75-1.06%

Last close · 2026-09-17

Latest quarter · ended 2026-03-31

Revenue

$28,785

Revenue YoY

-98.9%

Net profit

$-176.9M

EPS

$0.00

EPS estimate

$-0.34

Net margin

-614,683.2%

EPS came in at 0.00 against a street estimate of -0.34 — a beat of 100.0%.

Key statistics

Market cap

$895.3M

Forward P/E

0.0

P/B

2.10

Book value

$-0.17

EPS (TTM)

$-2.16

52-week high

$7.98

52-week low

$3.35

50-day MA

$4.56

200-day MA

$5.07

Beta

0.92

Analyst view

Analysts rate Inventiva Sa a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $14.62.

Shareholding

Institutions

41.80%

Largest institutional holders

Fund	Stake
Caligan Partners LP	3.46%
Samsara BioCapital, LLC	2.67%
Paradigm Biocapital Advisors LP	1.69%
Andera Partners	1.54%
Millennium Management LLC	1.49%
Trails Edge Capital Partners, LP	1.13%
Franklin Templeton Inc	1.04%
Squadron Capital Management LLC	1.03%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Inventiva Sa — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.